Caged Luciferin Probes for Rapid Bacterial Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting β-lactamase and carbapenemase-resistant bacterial strains are slow, prone to false negatives, and suffer from interference from nonspecific or autofluorescence signals in patient specimens, limiting their sensitivity and specificity.
Innovation Solution
Development of caged luciferin-based probes that emit bioluminescence upon β-lactamase or carbapenemase activation, allowing for rapid and high-throughput detection of resistant bacteria by using a cephalosporin or carbapenem moiety to create probes that generate low background signals, enhancing sensitivity and reducing culture time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If culture-based methods or automated liquid culture are used for detection, then sensitivity and specificity are maintained at 80-95%, but detection time increases to 1-2 days
Solution Approach 1:
The patent replaces traditional culture-based mechanical detection methods with a bioluminescence-based optical detection system. The probe uses a luciferin-luciferase reaction that produces light emission upon encountering β-lactamase activity, enabling rapid detection without requiring extended bacterial culture growth. This substitution reduces detection time from 1-2 days to significantly shorter periods while maintaining detection accuracy through the specific optical signal generated by the enzymatic reaction.
Solution Approach 2:
The invention changes the detection parameter from measuring bacterial growth (culture-based) to measuring bioluminescence intensity (light emission). By using a probe that converts β-lactamase enzymatic activity directly into a measurable optical signal, the system achieves rapid detection without the time-consuming culture expansion step, thereby resolving the contradiction between detection speed and accuracy.
2Difficulty of detecting and measuring
If fluorescent probes are used for detection, then detection capability is improved, but sensitivity is reduced due to interference from nonspecific or autofluorescence signals
Solution Approach 1:
The patent substitutes fluorescent detection (which requires excitation light and suffers from autofluorescence interference) with bioluminescence detection. The luciferin-luciferase system generates its own light emission without requiring external excitation, eliminating the source of autofluorescence interference. This substitution maintains strong detection capability while achieving superior sensitivity by removing the interfering excitation light component from the detection system.
Solution Approach 2:
The invention converts the potential harm of requiring excitation light (which causes autofluorescence interference) into a benefit by using a system that generates light spontaneously. The bioluminescence reaction produces photons directly from the enzymatic reaction between luciferin and oxygen, catalyzed by luciferase, turning the detection process into a self-luminous system that avoids all excitation-related interference.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The caged luciferin probes enable rapid and sensitive detection of β-lactamase and carbapenemase activities, facilitating timely diagnosis and appropriate treatment while minimizing antibiotic resistance spread, with improved sensitivity and specificity compared to existing methods.
Implementation Method 1
caged luciferin-based probes that emit bioluminescence upon β-lactamase or carbapenemase activation
Implementation Method 2
These enzymes could hydrolyze the amide bond of the β-lactam ring and inactivate the drugs
Data Source
AI summary
Caged luciferin-based probes become a luciferase substrate emitting bioluminescence upon β-lactamase/esterase activation. The inclusion of a cephalosporin moiety renders the probe capable of being used for the detection of a wide-range of β-lactamases and β-lactamase-expressing bacteria. Embodiments of a rapid high-throughput assay for the identification of β-lactamase-expressing bacteria is made possible by the use of such probes. In some embodiments the cephalosporin is substituted by a carbapenem moiety to generate carbapenem-caged luciferin carbapenem-cleavable probes capable of being used for the detection of a wide-range of carbapenem-expressing bacteria. Accordingly embodiments of a rapid high-throughput assay for the identification of carbapenem-expressing bacteria is made possible by the use of these probes.